Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the postmenopausal woman, low plasma oestrogen levels are due to the cessation of ovarian follicular activity, and residual oestrogen is thought to result from the adrenal glands and ovaries, both sources of androgens for peripheral oestrogen synthesis. In a study of 21 postmenopausal women with advanced breast cancer, Zoladex (goserelin), 3.6 mg depot, monthly, had no affect on the adrenal-derived androgens, but a direct effect on ovarian secretion of androgens is thought to have occurred. Thus, in such women, medical adrenalectomy is likely to produce an incomplete suppression of plasma androgens, but its combination with Zoladex may provide a new therapeutic option.

Original publication




Journal article


Horm Res

Publication Date



32 Suppl 1


209 - 212


Androgens, Breast Neoplasms, Buserelin, Delayed-Action Preparations, Estrogens, Female, Gonadotropins, Pituitary, Goserelin, Humans, Menopause